Buspirone And CBD Oil


Buy CBD Oil Online

A Placebo-Controlled Trial of Buspirone for the Treatment of Marijuana Dependence Authors McRae and Brady designed the study and wrote the protocol. Authors McRae, Brady, Killeen, Carpenter, and CBD drug interactions Drug interactions may take place if CBD is taken at the same time as another course or dose of medication. CBD can affect how our bodies process other drugs, which may

A Placebo-Controlled Trial of Buspirone for the Treatment of Marijuana Dependence

Authors McRae and Brady designed the study and wrote the protocol. Authors McRae, Brady, Killeen, Carpenter, and Simpson participated in the conduct of the study. Authors Carter and Wahlquist undertook the statistical analysis. All authors contributed to and have approved the final manuscript.


The present study investigated the potential efficacy of buspirone for treating marijuana dependence. Participants received either buspirone (maximum 60 mg/day) (n=23) or matching placebo (n=27) for 12 weeks, each in conjunction with motivational interviewing. In the modified intention-to-treat analysis, the percentage of negative UDS results in the buspirone-treatment group was 18 percentage points higher than the placebo-treatment group (95% CI: −2% to 37%, p=0.071). On self-report, participants receiving buspirone reported not using marijuana 45.2% of days and participants receiving placebo reported not using 51.4% of days (p=0.55). An analysis of participants that completed the 12-week trial showed a significant difference in the percentage negative UDS (95% CI: 7% to 63%, p=0.014) and a trend for participants randomized to the buspirone-treatment group who completed treatment to achieve the first negative UDS result sooner than those participants treated with placebo (p=0.054). Further study with buspirone in this population may be warranted; however, strategies to enhance study retention and improve outcome measurement should be considered in future trials.


Marijuana is the most commonly used drug in the world, with an estimated 166 million users globally (UNODC, 2008). The 2006 National Survey on Drug Use and Health reports that 97.8 million (39.8%) of Americans 12 years of age or older have tried marijuana at least once in their lifetime and 25.4 million (10.3%) used marijuana in the past year (SAMHSA, 2007). Lifetime prevalence rates of marijuana abuse and dependence among adults in the United States have been estimated at 7.2 and 1.3%, respectively (Stinson et al., 2006).

Results from the Epidemiological Catchment Area Survey demonstrated that marijuana abuse is significantly associated with affective disorders (Regier et al., 1990) with the odds of having an affective disorder being 3.8 times higher in individuals with a marijuana use disorder diagnosis. Anxiety disorders, in particular, may be related to continued marijuana use (Gruber et al., 1997), as users of marijuana report that its use relieves unpleasant feeling states such as anxiety. Data from the National Comorbidity Study indicate approximately a two-fold risk of generalized anxiety disorder in individuals with lifetime marijuana dependence (Agosti et al., 2002). Another study documented a 28.8% lifetime prevalence of anxiety disorders among those with marijuana use disorders (Conway et al., 2006).

The relationship between anxiety and marijuana withdrawal has also been explored. The concept of a marijuana withdrawal syndrome, characterized by irritability, anxiety, and insomnia, has recently been recognized (Kouri and Pope, 2000; Budney et al., 2004; Budney and Hughes, 2006; Copersino and Boyd, 2006). Budney and colleagues reported that high anxiety scores were correlated with increased withdrawal scores in marijuana-dependent adults (Budney et al., 1999). It is possible, therefore, that individuals continue to use marijuana to alleviate or avoid these withdrawal symptoms. The use of an anxiolytic agent may possibly improve substance use outcome measures in individuals attempting to reduce or stop marijuana use. However, limited research has focused on pharmacological agents in the treatment of marijuana use disorders (McRae et al., 2003; Levin et al., 2004; Nordstrom and Levin, 2007; Tirado et al., 2008). Buspirone is a non-benzodiazepine anxiolytic with little or no abuse potential (Lader, 1991). An open-label study of buspirone was shown to improve marijuana use outcomes (McRae et al., 2006), and the purpose of this study was to further explore these promising preliminary findings in a larger, placebo-controlled trial.


The study was a 12-week, double-blind, placebo-controlled trial of a flexible dose of buspirone (up to 60 mg/day) in marijuana-dependent individuals, conducted between April 2004 and September 2007. Patients were recruited primarily through newspaper advertisements and fliers. All procedures were conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki and received approval from the Medical University of South Carolina Institutional Review Board. All participants gave written, informed consent prior to study participation.

To be eligible for participation, individuals had to be between 18 and 65 years of age and meet DSM-IV criteria for current marijuana dependence. Exclusion criteria included dependence on any other substance (with the exception of caffeine or nicotine); history of psychotic disorder; current major depression or eating disorder; current treatment with a psychoactive medication; major medical illnesses; and pregnancy, nursing, or inadequate birth control.

The Structured Clinical Interview for DSM-IV (SCID-IV) (First et al., 1994) was used to assess for psychiatric exclusions. Marijuana use for the 90 days prior to study entry was estimated using Time-Line Follow-Back (TLFB) procedures (Sobell and Sobell, 1978), and TLFB data were collected weekly throughout the study. Weekly assessments included scales to assess marijuana craving (Marijuana Craving Questionnaire (MCQ); Heishman et al., 2001), and marijuana withdrawal symptoms (Marijuana Withdrawal Checklist; Budney et al., 1999). The Hamilton Anxiety Scale (HAM-A) (Hamilton, 1959) was administered at baseline, weeks 1–4, and weeks 6, 8, and 12. Semi-quantitative urine drug screens (UDSs) for cannabinoids were performed at baseline and weekly throughout the study. To note, initially twice weekly UDSs were collected; however the protocol was amended due to poor participant compliance and the concern that the requirement of multiple weekly clinic visits was affecting retention. UDSs were performed using the AXSYM® system from Abbott Laboratories.

Both groups received adjunctive motivational interviewing (MI) for the first four weeks of the treatment period. This intervention was modeled after the Drinker’s Check-Up (Miller et al., 1993). Participants completed a series of worksheets as part of the intake process (Marijuana Use Summary Sheet, Self-Efficacy Questionnaire, Marijuana Problem Scale, Reasons for Quitting Questionnaire; Steinberg et al., 2005). This information was then used to prepare personalized feedback reports which were used as a framework to discuss the participant’s frequency of marijuana use, problems related to use, reasons for quitting, and high-risk situations for use. Initially, participants completed two sessions; however, to improve treatment retention a third session was added. The first session occurred prior to medication initiation, and a second session occurred approximately one week later. A third session occurred at week 4 to follow-up on action plans (if any) and formation of short- and long-term goals.

Urn randomization (Stout et al., 1994) was used to determine treatment assignment. Urn variables used were age (less than 35 years of age or older), gender, and HAM-A score (less than 18 or 18 and above). Buspirone and placebo tablets were packaged in identical opaque gelatin capsules with cornstarch. Medication dosage was initiated at 5 mg buspirone or placebo twice daily and increased by 5–10 mg every three to four days as tolerated to a target dose of 60 mg/day. Medication side effects were evaluated weekly by a clinician by asking the participant open-ended questions such as “Have you had any problems or side effects since we saw you last (such as cold, flu, headache, nausea, or any other problem)?” The type of adverse event, severity of the adverse event, and the relationship to the study medication was recorded. Compliance was assessed by patient report and pill count. Subjects received nominal monetary reimbursement ($10) for time and travel associated with study visits; this compensation was added after approximately 30 participants were enrolled.


2.1.1 Sample Size Considerations

The sample size calculations for this study were based on the prediction that 20% of the placebo-treated participants would report a reduction in marijuana use and that 60% of the participants receiving buspirone would have a reduction in marijuana use. At the alpha=0.05 level of significance and 80% power, a sample size of 28 per group was necessary, but this number was inflated to account for anticipated attrition. In total, at least 40 participants per group were determined to be the minimum sample size. It is worth noting that while the estimated effect size (i.e., odds ratio of 6.0) was viewed at the time of planning as being clinically relevant, it was believed that should a smaller effect size be observed, the data and experience generated from this study would still be important.

2.1.2 Outcome measures

The primary outcome for this study was based on semi-quantitative urine drug screen for cannabinoids, simply denoted as a UDS result for the remainder of the manuscript. Submitted UDSs were deemed negative if the specimen contained less than 50ng/ml of cannabinoids. The difference in the percentage of negative UDS results between treatment groups served as the primary efficacy measure. In addition, secondary outcomes included: 1) time to the first negative UDS result (all subjects enrolled had a positive UDS at baseline), 2) summary measures of self-reported use (including percent days abstinent and mean amount used per using day), and 3) measures of marijuana craving (as measured by the MCQ), marijuana withdrawal symptoms, and anxiety as quantified by the HAM-A.

2.1.3 Statistical Methods

Two analytical approaches were used to test for between group differences in the primary endpoint. The first method was the traditional summary of percent negative UDS that is obtained by first by calculating the percent of negative UDS within participant then testing for between group differences on the calculated percentages. Since each participant’s dependent variable was a percentage (and inherently not normally distributed), between group differences were tested using the Wilcoxon Rank Sum test, the non-parametric equivalent to the two group student’s t test. For this analytical approach, two within-participant percentages of negative UDSs calculations were calculated. The first was the intention-to-treat approach that considered any weekly UDS to be positive if it were missing (i.e., the denominator for each participant was 12, the number of the study weeks, and the numerator was the observed number of negative urine drug screens). The second method assumed any missing UDSs were missing completely at random so that the within-participant percentage of negative UDS was simply the observed fraction of negative UDSs.

The second analytical method for testing for between group difference in percentage of negative UDS results (i.e., risk difference) was estimated using a generalized linear model (GLM) framework (McCullagh and Nelder, 1989). A GLM, as the name implies, is a robust modeling framework that allows for non-normally distributed dependent variables and alternative ways of “linking” the dependent variable to the independent variables of interest. To estimate the risk difference directly, the GLM was configured with the identity link (the same link function used in ordinary least squares regression), a binomial distribution for the dependent variable, and a systematic component (i.e., independent variables) of an intercept and an indicator variable for the main effect of the randomized treatment group. Configured in this manner, the beta-coefficient associated with the main effect of the treatment group was the primary parameter of interest. That is, a test of this beta-coefficient equal to zero is a test of the null hypothesis that there was no difference in the percentage of negative UDS results between the two groups. Generalized estimating equations (GEE) (Liang and Zeger, 1986) were used to account for the clustering of UDS results within a participant.

See also  CBD Oil For Tremors

Secondary analyses consisted of measuring the difference in self-reported use, assessing the effect of the behavioral intervention, and assessing the potential mediating effects of changes in anxiety. The same GLM/GEE framework used for the primary outcome was used in these analyses. To test for the potential of effect modification due to the behavioral sessions (quantified as either the per protocol number of sessions or the actual number received) on the primary analysis, the systematic component of the GLM/GEE framework was extended to include the main effect of the number of behavioral sessions and its interaction with the treatment group. For this analysis, the link in the GLM framework was changed from the identity link to the logit link to ensure the model-based estimates of the probability for a negative UDS were between 0 and 1; the inclusion of continuous covariates necessitated this change.

For secondary outcomes including anxiety, marijuana craving and withdrawal, between group differences on the change from baseline scores were tested using the Wilcoxon Rank Sum Procedure. Last observation carried forward (LOCF) was used to estimate the change from baseline to Week 12.

All primary analyses were conducted on the modified intention-to-treat (ITT) sample. This analysis set included all participants that were randomized and provided at least one post-randomization UDS assessment. For comparative purposes, demographic summaries of the full ITT sample ( Figure 1 , n=59) were computed; however, since nine of these subjects failed to provide any on-study UDS assessments, the results of the full ITT would be identical to the results of the modified ITT results unless the missing data were imputed. Sensitivity analyses were conducted on the subset of participants that completed the study. All analyses were conducted using the SAS System (version 9.1.3, Cary, NC). The type I error rate was established a priori at 0.05, and no corrections for multiple comparisons have been applied to reported p-values.

Progress of patients in the study.


3.1 Sample Description

The participant disposition through the study is present as Figure 1 . A total of 134 participants were consented, and 93 met initial eligibility and were randomized. Randomization occurred prior to comprehensive medical evaluation, and five randomized participants were deemed ineligible upon further examination. A significant number of participants (n=21) failed to return for the second baseline visit and were lost to follow up before distribution of study medication. The remaining eight participants were excluded for a variety of reasons including presence of other substance dependence (n=2), concomitant medications exclusions (n=2), personal reasons (n=2), and failure to complete necessary baseline examinations (n=1). One additional participant was excluded by the principal investigator when the data were determined to be unreliable. This participant received study medication, but there were significant concerns regarding treatment non-compliance confirmed by discussion with the participant; furthermore, the participant also belatedly reported use of a concomitant medication that would exclude study participation. The participant was discontinued from the study after one week and the data were not included in any analyses. The remaining 59 randomized subjects constituted the full ITT sample; however, only 50 participants were included in the modified ITT analysis set. The nine participants that were not included in the modified ITT did not provide any on study UDS results, although one participant did provide self reported data. Overall, there were no statistically significant differences in demographic variables between the two ITT definitions ( Table 1 ), but there was a trend for the nine excluded participants to have higher self reported use (97% days using prior to study vs. 89%, p=0.07). Within the modified ITT sample, there were no statistically significant differences between the two treatment groups with respect to baseline characteristics ( Table 1 ). For the remainder of this report, we report outcomes on the modified ITT sample, unless stated otherwise.

Table 1

Modified Intention to Treat Sample (ITT, n=50)
Full ITT Sample (n=59) Modified ITT Buspirone ( n=23) Placebo (n=27)
Domain Variable Mean SD Mean SD p-value

Mean SD Mean SD p-value
Age 31.4 9.8 31.6 10.2 0.97 29.5 8.4 33.4 11.3 0.32
Sex, N (%) male 52 88% 45 90% 0.29 19 83% 26 96% 0.17
Race, N (%) Caucasian 51 86% 43 86% 1.00 19 83% 24 89% 0.69
Psychiatric Measures
Hamilton Anxiety Rating Scale 9.1 6.6 9.1 6.9 0.67 10.3 7.1 8.1 6.7 0.24
Substance Use Measures
Self Efficacy Score 3.2 1.2 3.3 1.2 0.82 3.2 1.2 3.3 1.2 0.55
Reason for Quiting Score 10.9 6.2 11.0 6.6 0.76 12.1 7.3 10.2 5.8 0.34
Marijuana Problem Score 8.8 4.4 9.0 4.5 0.25 9.1 4.4 9.0 4.7 0.91
Marijuana Craving Questionnaire (MCQ)
MCQ: Compulsion 8.4 4.4 8.3 4.3 0.95 8.3 4.6 8.4 4.1 0.91
MCQ: Emotion 10.5 4.6 10.2 4.6 0.26 9.5 5.5 10.7 3.8 0.49
MCQ: Expectancy 13.0 4.4 12.9 4.4 0.84 12.4 4.0 13.3 4.8 0.46
MCQ: Purposefulness 13.3 5.2 13.2 5.3 0.86 12.5 6.1 13.9 4.5 0.35
MCQ: Total Score 45.1 14.4 44.6 14.4 0.59 42.6 15.9 46.3 13.1 0.40
Withdrawal checklist 18.6 10.4 17.9 9.4 0.70 18.6 7.4 17.4 10.9 0.50
Self-reported use based on 90 day time line follow back
% Days of TLFB with reported use 90% 15% 89% 16% 0.07 87% 20% 91% 11% 0.80
Amount Using Per Using Day 4.0 2.9 3.8 2.5 0.76 3.3 2.1 4.2 2.7 0.28

3.2 Primary Analysis

All modified ITT participants submitted at least one UDS after starting study medication. Four urine specimens were not evaluable at the laboratory, but the remaining 395 specimens were analyzable and were included in the primary analysis. Participants submitted between one and 23 urine specimens while on study medication (Mean (SD): 7.9 (5.3); Median (IQR): 8.5, (3 to 11)). The estimate of the intraclass correlation of UDS results within participant was 0.57.

Participants randomized to the placebo treatment condition had an estimated (i.e., model-based) probability of a negative UDS of 11% (95% CI: 1% to 21%) using all available UDS results ( Table 2 ). The estimated probability of a negative UDS in the buspirone treatment group was 18 percentage points higher (95% CI: −2% to 37%, p=0.071). These results were quite similar to the traditional participant-specific calculations described in the methods and presented in Table 2 ; however, due to their lower power, the p-values were larger.

Table 2

Outcome summary by treatment group

Buspirone Placebo Measure of Treatment Effect
Variable Estimate Estimate Description Estimate Standard Error p-value
Urine Drug Screens for Cannabis
Mean (SD) % Negative, ITT (all missed assumed positive) 20.3% (32.5%) 6.5% (16.2%) Wilcoxon Rank Sum Test N/A N/A 0.13
Mean (SD) % Negative, only observed specimens 27.6% (40.9%) 11.7% (27.8%) Wilcoxon Rank Sum Test N/A N/A 0.16
Model-based estiamte % negative

28.8% 11.0% Risk Difference 17.8% 9.9% 0.07
Timeline Follow-Back
% Days reporting no use

45.2% 51.4% Risk Difference −6.2% 10.4% 0.55
% Reduced days using relative to baseline

69.6% 85.2% Fisher’s exact N/A N/A 0.30
% Reduced amount using/using day relative to baseline

91.3% 92.6% Fisher’s exact N/A N/A 1.00
Hamilton Anxiety Rating Scale, mean (SD)
Total score −6.10 (7.11) −4.00 (5.68) Wilcoxon Rank Sum Test N/A N/A 0.40
Marijuana Craving Questionnaire, mean (SD)
Compulsion subscale −Q4.50 (4.70) −4.00 (4.72) Wilcoxon Rank Sum Test N/A N/A 0.97
Emotion subscale −5.25 (5.20) −3.88 (4.74) Wilcoxon Rank Sum Test N/A N/A 0.43
Expectancy subscale −5.40 (4.47) −5.84 (5.15) Wilcoxon Rank Sum Test N/A N/A 0.88
Purposefulness subscale −7.50 (5.61) −5.08 (5.05) Wilcoxon Rank Sum Test N/A N/A 0.17
Total score −22.65 (16.29) −19.40 (15.75) Wilcoxon Rank Sum Test N/A N/A 0.71
Withdrawal checklist, mean (SD)
Total score −10.87 (8.99) −10.40 (7.73) Wilcoxon Rank Sum Test N/A N/A 0.99

For the Intention-to-Treat (ITT) analysis, the denominators were n=23 for Buspirone and n=27 for Placebo. Only observed results that were negative were considered

Values are change from baseline using last observation carried forward method of imputation. One placebo subject did not have any post baseline scale-based

The time to first negative UDS result was consistent with these findings. There was a trend towards faster achievement of the first negative UDS in participants randomized to the buspirone treatment group compared to participants treated with placebo ( Figure 2 , p=0.098).

Survival analysis, modified ITT sample

No additional statistically significant results were observed on the secondary outcome measures ( Table 2 ). Overall, the vast majority of participants reduced the amount of use per using day, but no between group differences were observed (91% buspirone vs. 93% placebo; p=1.0).

3.3 Anxiolytic Effect (exploratory analysis)

As the study was designed, it was hypothesized that buspirone’s anxiolytic effects may contribute to reduced substance use through interactions with withdrawal symptoms. To explore this hypothesis, the treatment effect on the HAM-A scores as well as potential mediating effects of reductions in anxiety were examined. Participants treated with buspirone had a 6.1 (SD=7.1) point reduction in the HAM-A versus a 4.0 (SD=5.7) point reduction among those in the placebo arm, but the difference between groups did not near statistical significance (p=0.40) ( Table 2 ). However, when a participant’s change in HAM-A scores was used as a predictor in a GLM/GEE regression model (i.e., main effect of change in HAM-A only in the model), the change in HAM-A score was associated with associated with the probability of having a negative UDS result (p=0.03). In particular, for every one point increase in the HAM-A delta score (which indicates less improvement over the course of the study), the probability of observing a negative UDS decreased by 1.6 percentage points, or simply, large improvements in the HAM-A were associated with higher probabilities of having a negative UDS. When the main effect of the randomized treatment was added to this regression model, the statistical significance of the change in HAM-A diminished (p=0.09) as did the beta coefficient (reduced from − 1.6 to −0.9 percentage points per unit change), and the main effect of buspirone reached the threshold for statistical significance (p=0.025). The point estimate for the risk difference in this adjusted analysis was 20.3 percentage points, a value comparable to that in the unadjusted analysis ( Table 2 ).

Similar, albeit less pronounced, results were obtained using the change in withdrawal symptoms over the course of the study. No between group differences on the change in withdrawal symptoms were found ( Table 2 ), but participants with less improvement in withdrawal symptoms tended to have lower estimated probabilities of a negative UDS (p=0.06). When treatment group and change in withdrawal were modeled jointly, the main effect of treatment group remained marginally significant (p=0.07) and the estimated treatment effect was slightly attenuated (estimated risk difference of 16.2% instead of 17.8%).

3.4 MI Intervention Effect

The GLM modeling framework was used to explore the potential effect modification due to the MI intervention that accompanied the pharmacological treatment. No significant interaction of the number of per protocol MI sessions (2 or 3 sessions) with treatment was observed (p=0.49), and after removing the interaction term from the model, the main effect of the number of MI sessions was also non-significant (p=0.44). Together, these findings suggest that while the protocol was modified to include a third MI session, this did not affect the primary study findings. Similarly, the actual number of sessions attended (range 0 to 3) was modeled as a continuous variable along with its interaction with the treatment group. Both the interaction term and main effect of number of sessions were not statistically significant (p=0.21, p=0.40; respectively).

3.5 Completers Analysis

Exploratory analyses were conducted in the subset of participants that completed the study (n=24, Figure 1 ). In particular, the difference in the percentage of negative UDS results between the two groups was a 35 percentage point difference (95% CI: 7% to 63%, p=0.014). The percentage negative UDS for the placebo group remained comparable to the full data set (completers: 10.0%; modified ITT sample: 11.0%), so this increase in the absolute value of the risk difference is attributable to a greater increase in the probability of a negative UDS result in the buspirone group. Similarly, the Kaplan-Meier survival curves retained the similar overall shape to the modified ITT sample, and the logrank statistic comparing the two survival curves was marginally significant (p=0.054).

3.6 Safety and Tolerability

No serious adverse events were observed in the study. All reported adverse events were mild to moderate in severity. The majority (96%) of buspirone-treated participants experienced at least one adverse event compared to 78% of placebo-treated participants ( Table 3 ). Dizziness was reported more frequently for participants on buspirone (Relative Risk-RR=3.52, 95% CI 1.08 to 11.49). Dry mouth (RR=2.35), flushing/sweating (RR=2.93), and cold-like symptoms (RR=2.35) were also observed with greater frequency among buspirone-treated participants, but these relative risks did not reach significance. Other reported adverse events occurred in comparable frequencies in the two groups.

Table 3

Adverse event summary for the Modified Intention-to-Treat Sample

Buspirone (n=23) Placebo (n=27) Relative Risk
Adverse Event Freq. Percent Freq. Percent Estimate 95% CI
At least one AE 22 96% 21 78% 1.23 [0.99, 1.53]
Anxiety/depression 0% 1 4%
Dizziness 9 39% 3 11% 3.52 [1.08, 11.49]
Drowsiness 7 30% 7 26% 1.17 [0.48, 2.85]
Dry mouth 4 17% 2 7% 2.35 [0.47, 11.67]
Flushing/sweating 5 22% 2 7% 2.93 [0.63, 13.73]
Gastrointestinal 8 35% 8 30% 1.17 [0.52, 2.63]
Headache 9 39% 9 33% 1.17 [0.56, 2.46]
Insomnia 1 4% 2 7% 0.59 [0.06, 6.06]
Lightheaded/shakiness 4 17% 3 11% 1.57 [0.39, 6.28]
Metallic taste 1 4% 0%
Musculoskeletal 2 9% 2 7% 1.17 [0.18, 7.69]
Sexual dysfunction 1 4% 1 4% 1.17 [0.08, 17.74]
Sinus/allergies/flu 10 43% 5 19% 2.35 [0.94, 5.88]
Tingling 2 9% 0%
Unusual dreams 2 9% 2 7% 1.17 [0.18, 7.69]
Other 2 9% 2 7% 1.17 [0.18, 7.69]


In this small study, no significant differences between treatment groups were observed in the modified ITT analysis. However, there were trends for buspirone-treated participants to have a reduction in positive urine drug screens and to have shorter time to first negative UDS compared to placebo-treated participants. It is worth noting that the percentage of buspirone-treated participants with reduction in days of use relative to baseline was on par with sample size calculations (69.9% observed, 60% expected); however, the placebo-treated participants reduced use far above what was initially hypothesized (85% observed, 20% expected). These differences are in contrast to the urine drug screen findings which indicated a trend towards greater percentage of use among participants in the placebo-treatment condition.

These results suggest there may be some discordance between participant self-report and urine drug screen results, as there were no treatment group differences in TLFB analyses. A reduction from pre-treatment self-reported drug use was observed in both buspirone- and placebo-treated participants. It is difficult to validate self-report in marijuana using individuals due to the long excretion half-life of marijuana in urine (Eskridge and Guthrie, 1997). Creatinine normalization has been proposed as a method to differentiate new marijuana use from residual drug excretion (Huestis and Cone, 1998). However, the utility of creatinine normalization has not been well established with urine sampling conducted at weekly intervals. As noted previously, initially subjects were asked to provide two UDSs weekly. However, there was poor compliance with multiple clinic visits and concern that the increased visit burden was adversely affecting recruitment and retention, and these interim UDS results were not included in the primary analyses.

Changes in anxiety severity over the course of the study were found to be a significant predictor of urine drug screen results, and when the analysis adjusted for these changes the main effect of treatment group became significant. This latter finding, while not tested in a formal mediation setting, may suggest additional hypotheses to be tested in future studies.

The mechanism of action of buspirone has not been clearly established; however, buspirone has been shown to have high affinity for serotonin receptors (Glaser and Traber, 1983; Eison and Eison, 1984; Kastenholz and Crimson, 1984). Serotonin has been implicated in a variety of neuropsychiatric behaviors and disorders including mood, anxiety, appetite, sexual functioning, cognition, substance abuse, depression, and response to antidepressants and antipsychotics. Of relevance, a body of basic science evidence also implicates cannabinoid interactions with the serotonin system. Cannabidiol (CBD), a major component of cannabis, has been shown to be a modest affinity agonist at the 5-HT1A receptor (Russo et al., 2005). Further, cannabinoid receptor (CB1) agonists have been found to diminish 5-HT release (Nakazi et al., 2000) while antagonists have been shown to stimulate 5-HT release (Darmani et al., 2003). Additionally, Hill et al. (2005) demonstrated in an animal model that long-term administration of a synthetic cannabinoid agonist, HU-210, decreased 5-HT1A receptor activity. In vitro, buspirone has been shown to have activity at both presynaptic and postsynaptic 5-HT1A receptors (Robinson et al., 1990), leading to its classification as a partial 5-HT1A agonist. Although speculative, a possible mechanism for the improved marijuana use outcome measures observed in some buspirone-treated participants may be related to its interaction with the effects of cannabinoids at the level of the 5-HT1A receptor, such as having similar actions as cannabidiol or reversing a state of 5-HT1A downregulation caused by chronic marijuana use.

Participants retained for the entire treatment period had improved outcomes with buspirone treatment. A significant number of participants did not complete the screening period. Poor retention with this population has been reported by others (Levin et al., 2004). Strategies to improve retention may prove useful in future pharmacotherapy studies. For example, contingency management has been shown to be effective in increasing retention and improving medication compliance and treatment outcomes in adults with substance use disorders (Carroll et al., 2001; Carroll et al., 2002; Higgins et al., 1994; Preston et al., 1999).

Buspirone appeared to be well-tolerated in this population, with no serious adverse events reported and no difference in rates of adverse events between participants receiving buspirone or placebo, with the exception of dizziness. However, it should be noted that future research, with a much larger sample, is needed to further assess the safety profile of buspirone in marijuana-dependent individuals since even relatively common adverse events, with a prevalence as high as 13%, could have been unobserved in this sample. This calculation is based on the “Rule of Threes” for determining the approximate upper limit of a confidence interval on the rate of occurrence of adverse events when no events are observed (Van Belle, 2002). Thus, subsequent studies may yield additional adverse effects.

This study has several limitations. The sample size was small, and a significant number of participants did not complete the 12-week trial period. As noted above, the use of creatinine normalized urine cannabinoid levels proved difficult; therefore, it is not possible to validate the self-report marijuana use data that were collected. Also, the treatments tested reflected a combination of buspirone + MI versus MI alone, and thus are not a direct test of medication efficacy per se. The MI intervention was included here based on the primary rationale that a true placebo control group (i.e., without any treatment at all) would be unethical (Carroll et al., 2004). A limitation of the study’s efficacy findings stems from the modified ITT definition. The modification came from including only those subjects with at least one post-randomization assessment instead of including all randomized subjects. The modified definition was used due to the enrollment/randomization procedures used in the study. In particular, as urn randomization was used, it was necessary to collect baseline data prior to randomization by the central pharmacy. Thus, two baseline visits were needed—one to consent, screen, and collect randomization data and another to confirm eligibility criteria and dispense blinded medication to those that were eligible. As Figure 1 illustrates, 34 randomized participants did not receive study drug at the second baseline visit. An additional nine participants did return to the second baseline visit to receive study medication but failed to return to any subsequent visits. Under ITT, these participants should be included in the analysis, but these nine participants did not contribute to the preliminary description of safety and efficacy in this population. As such, these participants were excluded from this preliminary investigation (i.e., their data were not imputed for the primary analysis). Finally, as noted in the methods, several protocol changes were made during the course of the study in efforts to enhance retention and recruitment.

In spite of these limitations, the study results are suggestive that buspirone may have some utility in reducing marijuana use in dependent individuals, and that further study with larger sample sizes may be warranted in this challenging population. Interventions to enhance treatment retention and improvements in measurement of marijuana use outcomes should be incorporated in future trials.


We thank Ms. Kathleen White, who assisted with the preparation of this manuscript.

Role of Funding Source

Funding for this study was provided by NIDA Grants K23DA15440 (McRae), K23DA020482 (Carpenter), and K24DA00435 (Brady). NIDA had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.


Publisher’s Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest

Authors McRae and Brady have received grant support from Bristol-Myers Squibb. Author Brady has received honoraria from Bristol-Myers Squibb. All other authors declare that they have no conflict of interest.

CBD drug interactions

Drug interactions may take place if CBD is taken at the same time as another course or dose of medication. CBD can affect how our bodies process other drugs, which may impact how much of the medication ends up in our system as well as alter its reaction in the body, potentially causing negative side effects.

This article explores possible CBD drug interactions based on the effect that CBD has on the cytochrome P-450, a system in the body that is responsible for processing many different drugs and medications.

Before taking a new medication or food supplement it’s highly important to consult your doctor or healthcare professional. This article does not substitute for medical advice.

CBD and beta blockers ( β-blockers)

CBD has been linked with lowering blood pressure, however can have negative interactions with beta blockers and other blood pressure medication if taken together. CBD can affect how our bodies process beta blockers and can cause undesired effects – consult your prescribing doctor.

CBD and statins

Cholesterol reducing medications like statins can be impacted by CBD. CBD can pre-occupy the body’s system for processing certain drugs, this can cause medicines to remain in one’s system for longer, resulting in a potentially dangerous accumulation – consult your prescribing doctor.

CBD is safe:

CBD is a naturally occurring extract of the cannabis plant and many people use it as a daily supplement. It is non-addictive and non-psychoactive, meaning it won’t get you high like the other cannabis extract, THC.

In November 2017 the World Health Organisation (WHO) released its assessment of CBD, where it described the substance as having a “good safety profile” and noted that there were “no public health related problems associated with the use of pure CBD”. Despite this good safety profile, CBD does impact how your body processes other drugs and medications, which, if unaccounted for, can cause your body harm.

How CBD is processed in the body

Within the body, CBD is broken down by CYP enzymes and then processed by the body’s cytochrome P-450 system, which is also responsible for processing and metabolising a number of other drugs. A side effect of CBD is that it preoccupies the cytochrome P-450 system, slowing down the processing of particular drugs.

If your body’s cytochrome P-450 system is busy metabolising CBD rather than your medication, it can cause the medicine to remain in your system for longer than it is meant to. In some cases this may result in the medication accumulating or building up in the body to potentially toxic levels.

CBD and grapefruit

Naturally occurring compounds in grapefruit also impact CYP enzymes, just as CBD does. That’s why it’s recommended to avoid grapefruits and their juice while taking certain medicines. If a warning like this exists on your current medications, it is an indication that they may also be impacted by CBD.

The myth of the “two-hour rule” for taking CBD while on other medications

A worrying trend among online CBD communities and forums is risky and careless advice being given around taking CBD with other medications. Known as the “two-hour rule”, many community members looking to help newcomers advise a two-hour gap between taking other medications and CBD, in order to “give the liver a break” and avoid drug interaction.

While given in good nature, and far better than not leaving any gap, this kind of advice is risky given the vastly different medications, conditions and situations people are in. The advice should be that anyone taking other medication should consult their doctor before supplementing CBD products. A two-hour window is not enough time to guarantee that CBD and other medicines will not interact in a negative or dangerous way in your body.

CBD and alcohol

Despite no negative interactions having been reported between CBD and alcohol, it’s still advisable to exercise caution and be wary of excessive alcohol consumption in combination with CBD use, as both substances are processed by the liver.

It’s noteworthy that CBD can actually reduce blood alcohol levels if taken with alcohol. The study ‘Interaction of cannabidiol and alcohol in humans’ found:

“The combination of alcohol plus CBD resulted in significantly lower blood alcohol levels compared to alcohol given alone”.

CBD can also be a useful tool for recovering alcoholics, as it can help alleviate some of the symptoms of alcohol withdrawals and alcohol addiction.

CBD and recreational cannabis

No negative interactions having been reported between CBD and recreational cannabis use. In fact, CBD has shown to counteract some of the negative side effects of recreational cannabis, particularly anxiety. Many use CBD bud or flowers as an alternative to cannabis when trying to quit or cut down usage.

How to use hemp buds / CBD bud

CBD-rich strains of cannabis are an exciting product of the CBD and medicinal cannabis movement. Hemp buds offer an alternative to CBD oil as a source of CBD that can be smoked, vaped or used to make edibles and ingested.

CBD drug interaction warnings

The medications and substances highlighted in the following section have the potential to have an interaction with CBD, as many are processed by the cytochrome P-450 system. This list is not exhaustive and there are many other medications that may interact with CBD.

The result of the CBD/drug interaction is different for each, potentially increasing or decreasing the effectiveness of the medication, resulting in possibly dangerous side effects if not taken into account by your medical professional. This doesn’t mean the medications cannot be taken alongside CBD, but it’s of utmost importance you notify your doctor.

CBD and epilepsy treatments:

In clinical studies CBD has reduced the severity of seizures caused by epilepsy. However, some study participants experienced negative side effects from CBD interacting with their other epilepsy medications, such as Carbamazepine (Tegretol). Possible side effects include diarrhea, vomiting, fatigue and pyrexia (increased body temperature).

Consulting your doctor before treating epilepsy with CBD is crucial, as CBD interactions with epileptic medicines have been proven.

CBD and chemotherapy

CBD interacts with many chemotherapy drugs. CBD can increase the amount of time it takes for the body to process the chemotherapy drugs, resulting in a toxic buildup.

These are some common chemotherapy drugs which are processed by the cytochrome P-450 system and could strongly interact with CBD:

  • Etoposide (VePesid, Eposin, Etopophos)
  • Methotrexate
  • Paclitaxel (Taxol)

CBD with heart and cardiovascular medications

CBD has the potential to interact with many different heart medications, such as statins, a class of lipid-lowering medication and beta blockers ( β-blockers), which are medications that treat abnormal heart rhythms and are employed following heart attacks. Examples of heart medications that have interaction warnings include:

  • Ticagrelor (Brilinta)
  • Quinidine
  • Pitavastatin (Pravachol)
  • Talinoloa
  • Atorvastatin (Lipitor)
  • Celiprolol (Celicard)
  • Amiodarone (Cordarone)
  • Clopidogrel (Plavix)
  • Carvedilol (Coreg)
  • Nifedipine (Adalat, Procardia)
  • Valsartan (Diovan)

CBD and antidepressants

While most antidepressants do not interact with CBD, it’s still advisable to let your healthcare provider know you plan to start supplementing CBD. As always, reducing or tapering off antidepressant medication without medical supervision is not advised.

The anti-anxiety medication Buspirone, sold as BuSpar, is used to treat generalised anxiety disorder and is also often prescribed in addition to antidepressants. Buspirone is processed in the liver by cytochrome P-450 and may have a strong drug interaction with CBD, just as its warning not to consume it with grapefruit suggests.

Another antidepressant that comes with a strong interaction warning is Clomipramine (Anafranil).

CBD and blood pressure medications (calcium channel blockers)

Calcium channel blockers, blood thinners, and medications treating blood pressure and abnormal heart rhythms have a strong interaction warning with CBD. For example, CBD reduces the body’s ability to break down the prescription blood thinner warfarin, thereby amplifying its intended effect. Other examples of medications that may interact with CBD include:

  • Valsartan (Diovan)
  • Verapamil (Calan, Isoptin, Verelan)
  • Nifedipine (Adalat, Procardia)
  • Diltiazem (Cardizem)
  • Isradipine (DynaCirc)
  • Torsemide (Demadex)
  • Felodipine (Plendil)
  • Amlodipine (Norvasc)

CBD and sedative medications (benzodiazepine)

Benzodiazepines (sometimes called ‘benzos’) are used for treating: anxiety, insomnia, nausea, depression and panic attacks. CBD can slow down the body’s ability to process some benzodiazepines, namely the widely used alprazolam (Xanax) and diazepam (Valium). This may result in higher blood concentrations of the drug, causing side effects. Other common benzodiazepines which may have an interaction with CBD include:

  • Alprazolam (Xanax)
  • Triazolam (Halcion)
  • Diazepam (Valium)
  • Midazolam (Versed)
  • Pitavastatin (Pravachol
  • Quazepam (Doral)
  • Triazolam (Halcion)

CBD and antibiotics

Fluoroquinolone antibiotics in particular can interact with CBD. They are commonly used to treat a variety of illnesses, such as respiratory and urinary tract infections. Examples include:

  • Ciprofloxacin (Cipro)
  • Gemifloxacin(Factive)
  • Levofloxacin (Levaquin)
  • Moxifloxacin(Avelox)
  • Norfloxacin (Noroxin)
  • Ofloxacin (Floxin)

Other medications that have CBD interaction warnings:

  • Cholesterol treatment: Lovastatin (Mevacor)
  • Anti-fungal medications: Ketoconazole (Nizoral) & Itraconazole (Sporanox)
  • Anti-inflammatory drug: Troglitazone and Methylprednisolone
  • Anti-histamines: fexofenadine (Allegra) & Terfenadine (Seldane)
  • Viagra (Sildenafil)
  • Cholesterol and lipid-lowering medication:Simvastatin (Zocor)
  • Malaria medications: Artemether (Artenam, Paluther) & Halofantrine
CBD cream for pain

Regularly using a topical cannabidiol (CBD) cream is an effective source of targeted pain relief for many, especially for people suffering from multiple sclerosis, arthritis, or those who often have sore or inflamed muscles.

How useful was this post?

Click on a star to rate it!

Average rating 4 / 5. Vote count: 1

No votes so far! Be the first to rate this post.